

**VOYDEYA  
(danicopan)**

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age or older

### **Diagnosis**

Patient must have the following:

Extravascular hemolysis associated with paroxysmal nocturnal hemoglobinuria (PNH)

**AND ALL** of the following:

- a. Documented baseline value for hemoglobin (Hgb)
- b. Used in combination with Soliris (eculizumab) or Ultomiris (ravulizumab)
- c. Vaccination against encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type B at least 2 weeks prior to initiation [unless Voydeya (danicopan) treatment cannot be delayed]
- d. Prescriber is enrolled in Voydeya REMS program

## **Prior - Approval Limits**

**Quantity** 600 mg per day

**Duration** 6 months

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

### **Diagnosis**

Patient must have the following:

Extravascular hemolysis (EVH) associated with paroxysmal nocturnal hemoglobinuria (PNH)

**AND ALL** of the following:

- a. Increase in hemoglobin (Hgb) from pretreatment baseline



**BlueCross  
BlueShield**

Federal Employee Program.

**VOYDEYA  
(danicopan)**

- b. Used in combination with Soliris (eculizumab) or Ultomiris (ravulizumab)
- c. Absence of unacceptable toxicity from the drug
- d. Prescriber is enrolled in Voydeya REMS program

**Prior - Approval *Renewal* Limits**

**Quantity** 600 mg per day

**Duration** 12 months